In this interview from the 2019 Kidney Cancer Research Summit and published in the journal CURE, Dr Sumanta Pal, a medical oncologist at City of Hope, California, USA discusses the expanding field of kidney cancer treatment and what this means for patients with renal cell carcinoma (RCC).

During the interview, Dr Pal discusses the use of PARP inhibitors, vaccination-based strategies and emerging therapies such as tivozanib for the treatment of metastatic RCC.

Read Dr Pal’s interview in CURE here